Understanding the Role of GPNMB and Immune Cell Interactions in Breast Cancer Metastasis

Metastasis remains the leading cause of death in cancer patients, driven by complex changes within the tumor microenvironment (TME). Specifically, triple-negative breast cancer (TNBC), characterized by the absence of estrogen, progesterone, and HER2 receptors, is known for its aggressive nature and high tendency for recurrence and spread.

Recent research conducted by scientists at the University of Tsukuba has unveiled crucial mechanisms that promote TNBC progression. The study highlights the glycoprotein non-metastatic melanoma protein B (GPNMB), which is significantly overexpressed in TNBC cells. This protein alters the TME by transforming macrophages into immunosuppressive tumor-associated macrophages (TAMs), thereby facilitating tumor growth and metastasis. The research is published in the Proceedings of the National Academy of Sciences.

GPNMB undergoes specific modifications with cancer-associated sialic acids, allowing it to bind selectively to Siglec-9, an immune receptor present on macrophages. This binding steers macrophages toward an immunosuppressive state, increasing the epithelial-mesenchymal transition (EMT)—a process that enhances cancer cell mobility and invasiveness. Furthermore, GPNMB creates a feedback loop that amplifies its own expression, encouraging the spread of immune suppressor cells within the TME.

Experimental data from mouse models show that inhibiting GPNMB or Siglec-E (the mouse equivalent of Siglec-9) significantly reduces IL-6-driven EMT and metastatic spread. These findings point to the GPNMB-Siglec-9 pathway as a key driver behind TNBC progression and a promising target for innovative immunotherapeutic strategies.

This research deepens our understanding of how cancer cells manipulate immune interactions to promote metastasis and suggests potential avenues for targeted therapy that could improve outcomes for patients with this challenging form of breast cancer.